GKOS Company Profile and Key Details

Q: Who are the executives of GKOS?

Dr. Mory Gharib Ph.D.Co-FounderMr. David S. HaffnerSenior Vice President of New TechnologiesMs. Michele M. AllegrettoSenior Vice President of HRMs. Jane E. RadySenior Vice President of Corporation Strategy & Bus. Devel.Mr. Thomas William BurnsChairman & Chief Executive OfficerMr. Joseph E. GilliamPres & Chief Operating OfficerMr. Alex R. ThurmanSenior Vice President & Chief Financial OfficerMr. Chris M. CalcaterraExecutive Vice President of Global Commercial OperationsDr. Tomas Navratil Ph.D.Chief Devel. OfficerMr. Christopher William LewisVice President of Investor Relations & Corporation AffairsMs. Diane W. BiagiantiSenior Vice President & Gen. CounselMs. Diana A. SchererVice President of Compliance & Deputy Gen. Counsel

NYSE : GKOS

Glaukos

$138.97

-4.85-3.37%

Open: 11:34 AM

59.46

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Glaukos Corporation (GKOS) stock declined over -3.37%, trading at $138.97 on NYSE, down from the previous close of $143.82. The stock opened at $138.36, fluctuating between $134.32 and $140.64 in the recent session.

Stock Snapshot

143.82

Prev. Close

8.16B

Market Cap

134.32

Day Low

-42.11

P/E Ratio

-3.3

EPS (TTM)

-1.6

Cash Flow per Share

138.36

Open

58.73M

Number of Shares

140.64

Day High

96.61%

Free Float in %

9.45

Book Value

565.21K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 20, 2026	140.95	146.71	137.83	143.82	951.68K
May 19, 2026	141.32	142.85	137.32	139.90	728.87K
May 18, 2026	144.99	148.11	141.52	142.18	814.29K
May 15, 2026	142.27	144.16	140.91	144.01	978.74K
May 14, 2026	137.73	142.20	136.34	142.15	532.59K
May 13, 2026	135.18	138.34	133.22	137.29	485.03K
May 12, 2026	135.10	137.20	133.11	136.36	431.84K
May 11, 2026	132.36	136.26	130.64	135.37	807.82K
May 08, 2026	135.12	135.26	130.04	133.52	454.48K
May 07, 2026	136.35	137.34	132.19	134.15	349.21K
May 06, 2026	133.69	136.41	131.35	135.27	887.16K
May 05, 2026	137.10	137.10	131.93	133.42	674.38K
May 04, 2026	139.68	141.22	134.74	135.85	923.72K
Apr 30, 2026	141.50	145.50	130.90	143.67	2.41M
Apr 29, 2026	117.84	120.07	113.00	116.96	961.38K
Apr 28, 2026	122.21	123.05	118.70	119.63	492.88K
Apr 27, 2026	121.57	124.38	120.82	122.07	797.54K
Apr 23, 2026	121.25	123.21	119.84	120.87	473.88K
Apr 22, 2026	123.50	126.39	120.64	121.65	449.84K
Apr 21, 2026	123.98	125.30	121.17	122.11	492.73K

Contact Details

Aliso Viejo, CA 92672

United States

https://www.glaukos.com 949 367 9600

About Company

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Stock Peers

PEN

0.83+0.25%

Penumbra, Inc.$327.38 SYK

3.74+1.18%

Stryker Corporation$321.49 BIO

6.81+2.42%

Bio-Rad Laboratories, Inc.$287.86 BIO-B

9.17+3.43%

Bio-Rad Laboratories, Inc.$276.60 STE

1.55+0.72%

STERIS plc$215.97 ITGR

1.05+1.16%

Integer Holdings Corporation$91.49 ABT

-0.46-0.52%

Abbott Laboratories$88.36 ZBH

-0.7-0.81%

Zimmer Biomet Holdings, Inc.$85.38 GMED

4.1+5.13%

Globus Medical, Inc.$84.03 EW

0.81+0.99%

Edwards Lifesciences Corporation$82.97

Company Overview

Glaukos Corporation (NYSE:GKOS) closed at $138.97 USD, losing -$4.85 (-3.37%) from the previous close of $143.82. The stock is currently mid-range between its 52-week high and low $73.16 and $148.11. With a market capitalization of about $8.16 billion, Glaukos Corporation is classified as a mid-cap and shows market-like volatility (beta ~0.95). Key stats such as the average daily volume over the past year has been around 735.98 thousand shares, in line with its 52-week average. Headquartered in Aliso Viejo, CA, Glaukos Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Thomas William Burns, the company employs approximately 995 people and listed since June 25, 2015. Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

Technical Performance

GKOS has shown sold momentum, gaining 11.31% over the past week and 41.62% over the past quarter, though year-to-date performance is up 9.33%. Short-term trend indicators are mixed aligned (SMA20 4.99%, SMA50 4.93%, SMA200 23.37%). The stock’s 14-day RSI is 57.38 (neutral), while the ATR of 5.22 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -6.76% below its high and over 65.98% above its low. Average 10-day trading volume of 716.36 thousand shares is in line with the 3-month average of 709.62 thousand, indicating normal recent market interest.

Valuation Metrics

Glaukos Corporation trades at a P/E ratio of -44.4, slightly below the S&P 500 average, with a price-to-sales ratio of 15.43 and a price-to-book ratio of 12.53 reflecting a rich premium to book value. The P/FCF stands at -460.41, also below market averages. Compared to sector medians, Glaukos Corporation P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Glaukos Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$40.60. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Glaukos Corporation generated EPS of -$3.27 over the past year. Five-year average earnings growth is -3.95%. The latest quarter delivered EPS of -$0.18. The next quarter is forecast at -$0.27. Next year's EPS is expected at $11.28. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 25 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $162.00 to $92.00. The high target offers 12.64% upside. The low target suggests -36.03% downside. The mean target is $127.94. This offers -11.04% upside. Glaukos Corporation earnings surprise history is a mixed track record. The quarter that ended April 29, 2026, missed forecasts by -40.0%. The prior quarter beat by 27.27%. Over the last six quarters, Apple has recorded several small beats. These include 5.26% in February 20, 2025.

Shareholding & Insider Activity

Glaukos Corporation has 57.35 million shares outstanding. The public float is 55.40 million shares, elevated short interest at 9.20% of float. This equals 3.82 million shares. The short ratio is 3.55 days. Institutional investors hold 111.03% of the float. Insiders own 3.31%. Calcaterra Chris M. holds 211.02 thousand shares, Burns Thomas William has 153.78 thousand shares and Navratil Tomas has 90.37 thousand shares. Over the past six months, insider transactions show net selling. They sold 253.96 thousand shares across 17 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Glaukos generated $314.71M in revenue, or $6.50 per share. Gross margin was 75.99%, operating margin -40.89%, and net profit margin -42.79%. Returns are negative, with ROA at -14.32% and ROE at -29.16%.
On valuation metrics, Glaukos trades at a P/E of -44.40, P/S of 15.43 and P/B of 12.53. The current ratio is 5.43 and quick ratio is 4.73. Operationally, the company’s inventory turnover is 1.94 and cash conversion cycle is 209.82 days. Debt-to-equity is 0.15, supported by a cash flow-to-debt ratio of -0.09.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Glaukos posted revenue of $314.71M, down slightly from $282.86M in the prior quarter. Gross profit was $239.14M (margin 75.99%). Operating income was - $128.70M (margin -40.9%). Net income was- $134.66M (EPS - $2.78).
The company ended the quarter with $295.43M in cash and short-term investments, a total debt of $383.74M, and net debt of $290.27M. Total assets were $940.41M, with equity of $461.77M. Financials further reflected weakness, with operating cash flow of - $57.76M, free cash flow of - $78.01M, and capital expenditures of - $20.25M.

Price Forecast & Outlook

Our AI price prediction model suggests that Glaukos Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.57%, with price expected at $151.83 by June 03, 2026, within a range of $146.55 to $156.90 3-Month Outlook: Projected fall of -2.34%, reaching $140.46 by August 18, 2026, with a range of $134.23 to $146.12. 1-Year Outlook: Projected gain of 5.88%, with price at $152.28 by May 20, 2027, within a range of $143.00 to $159.70.

Key Takeaways

Glaukos Corporation (NYSE:GKOS) shares are flat 9.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Glaukos Corporation trading at a premium to the broader market with a P/E of -44.4. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $110.44, suggesting -23.21% downside. Our AI forecast model points to short-term strength (5.57% over two weeks), a medium-term fall (-2.34% over three months), and a longer-term gain (5.88% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Glaukos Corporation (GKOS) stock price?

Glaukos Corporation (NYSE: GKOS) stock price is $138.97 in the last trading session. During the trading session, GKOS stock reached the peak price of $140.64 while $134.32 was the lowest point it dropped to. The percentage change in GKOS stock occurred in the recent session was -3.37% while the dollar amount for the price change in GKOS stock was - $4.85.

GKOS's industry and sector of operation?

The NYSE listed GKOS is part of Medical - Devices industry that operates in the broader Healthcare sector. Glaukos Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GKOS?

Dr. Mory Gharib Ph.D.
Co-Founder
Mr. David S. Haffner
Senior Vice President of New Technologies
Ms. Michele M. Allegretto
Senior Vice President of HR
Ms. Jane E. Rady
Senior Vice President of Corporation Strategy & Bus. Devel.
Mr. Thomas William Burns
Chairman & Chief Executive Officer
Mr. Joseph E. Gilliam
Pres & Chief Operating Officer
Mr. Alex R. Thurman
Senior Vice President & Chief Financial Officer
Mr. Chris M. Calcaterra
Executive Vice President of Global Commercial Operations
Dr. Tomas Navratil Ph.D.
Chief Devel. Officer
Mr. Christopher William Lewis
Vice President of Investor Relations & Corporation Affairs
Ms. Diane W. Biagianti
Senior Vice President & Gen. Counsel
Ms. Diana A. Scherer
Vice President of Compliance & Deputy Gen. Counsel

How GKOS did perform over past 52-week?

GKOS's closing price is 96.58% higher than its 52-week low of $73.16 where as its distance from 52-week high of $148.11 is -2.9%.

How many employees does GKOS have?

Number of GKOS employees currently stands at 995.

Link for GKOS official website?

Official Website of GKOS is: https://www.glaukos.com

How do I contact GKOS?

GKOS could be contacted at phone 949 367 9600 and can also be accessed through its website. GKOS operates from 229 Avenida Fabricante, Aliso Viejo, CA 92672, United States.

How many shares of GKOS are traded daily?

GKOS stock volume for the day was 565.21K shares. The average number of GKOS shares traded daily for last 3 months was 735.98K.

What is the market cap of GKOS currently?

The market value of GKOS currently stands at $8.16B with its latest stock price at $138.97 and 58.73M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	995
Beta	0.78
Sales or Revenue	$314.71M
5Y Sales Change%	0.255%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

GKOS Company Profile and Key Details

Glaukos

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways